Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
214.40
+5.40 (2.58%)
Jun 6, 2025, 4:08 PM HKT

Duality Biotherapeutics Company Description

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others.

The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs.

It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC.

The company was incorporated in 2019 and is headquartered in Shanghai, China.

Duality Biotherapeutics, Inc.
Country Cayman Islands
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 170
CEO Zhongyuan Zhu

Contact Details

Address:
Full floor, 11th Floor
Shanghai
China
Phone 86 21 2601 8730
Website dualitybiologics.com

Stock Details

Ticker Symbol 9606
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number KYG2929M1087
SIC Code 2836

Key Executives

Name Position
Zhongyuan Zhu Chief Executive Officer
Shaoren Zhang Chief Financial Officer